Skip to main content

Advertisement

SpringerLink
Log in

Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties

  • Original Article
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

The present research aims to study the effects of guluronic acid (G2013) on gene expression levels of the T-bet, GATA3, RORγt, AHR, and FOXP3 transcription factors and on gene expression of their related cytokines following oral administration of this drug in ankylosing spondylitis (AS) patients. In this trial (clinical trial identifier: IRCT2016091813739N4), 14 AS patients and 12 age- and sex-matched healthy individuals were enrolled. The level of transcription factors’ gene expression and expression of their related cytokines were measured by quantitative real-time PCR, before and 3 months after G2013 therapy. Our data indicated that the gene expression levels of the T-bet and IFN-γ were not significantly reduced during 12 weeks of treatment with G2013 (p > 0.05). The findings showed that the gene expression levels of the GATA3 and IL-4 increased significantly during 12 weeks of treatment with G2013 (p < 0.05). In addition, gene expression levels of the RORγt, IL-17, AHR, and IL-22 decreased significantly during the 12-week treatment with G2013 (p < 0.05). Moreover, the gene expression level of the FOXP3 increased significantly during 12 weeks of treatment with G2013, but the gene expression level of IL-10 did not increase significantly (p < 0.05, p > 0.05, respectively). The present study showed that oral intake of G2013 was able to modify the severity of articular and inflammatory symptoms of AS through reducing the gene expression levels of the RORγt, IL-17, AHR, and IL-22 and increasing the gene expression levels of the GATA3, IL-4, and FOXP3.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Reference

  1. Dakwar E, Reddy J, Vale FL, Uribe JS. A review of the pathogenesis of ankylosing spondylitis. Neurosurg Focus. 2008;24:E2.

    Article  PubMed  Google Scholar 

  2. Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev. 2010;233:162–80.

    Article  CAS  PubMed  Google Scholar 

  3. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63:1099–112.

    Article  CAS  PubMed  Google Scholar 

  4. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650–7.

    Article  Google Scholar 

  5. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway. Ann Rheum Dis. 1985;44:359–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tsui FW, Tsui HW, Akram A, Haroon N, Inman RD. The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. Appl Clin Genet. 2014;7:105–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61:iii8–18.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Brown MA. Non-major-histocompatibility-complex genetics of ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2006;20:611–21.

    CAS  PubMed  Google Scholar 

  9. Mahmoudi M, Jamshidi AR, Amirzargar AA, Farhadi E, Nourijelyani K, Fallahi S, et al. Association between endoplasmic reticulum aminopeptidase-1 (ERAP-1) and susceptibility to ankylosing spondylitis in Iran. Iran J Allergy Asthma Immunol. 2012;11:294–300.

    CAS  PubMed  Google Scholar 

  10. Roberts AR, Vecellio M, Cortes A, Knight JC, Cohen CJ, Wordsworth BP. Investigation of a possible extended risk haplotype in the IL23R region associated with ankylosing spondylitis. Genes Immun. 2017;18:105–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Madej M, Nowak B, Świerkot J, Sokolik R, Chlebicki A, Korman L, et al. Cytokine profiles in axial spondyloarthritis. Reumatologia. 2015;53:9–13.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Sveaas SH, Berg IJ, Provan SA, Semb AG, Olsen IC, Ueland T, et al. Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol. 2015;44:118–24.

    Article  CAS  PubMed  Google Scholar 

  13. Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, et al. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity. 2012;37:660–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lau MC, Keith P, Costello ME, Bradbury LA, Hollis KA, Thomas R, et al. Genetic association of ankylosing spondylitis with TBX21 influences T-bet and pro-inflammatory cytokine expression in humans and SKG mice as a model of spondyloarthritis. Ann Rheum Dis. 2017;76:261–69.

    Article  CAS  PubMed  Google Scholar 

  15. Limón-Camacho L, Vargas-Rojas MI, Vázquez-Mellado J, Casasola-Vargas J, Moctezuma JF, Burgos-Vargas R, et al. In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol. 2012;39:830–5.

    Article  PubMed  Google Scholar 

  16. Zhang Y, Zhang Y, Gu W, He L, Sun B. Th1/Th2 cell’s function in immune system. Adv Exp Med Biol. 2014;841:45–65.

    Article  CAS  PubMed  Google Scholar 

  17. Wang C, Liao Q, Hu Y, Zhong D. T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Exp Ther Med. 2015;9:250–56.

    Article  CAS  PubMed  Google Scholar 

  18. Wang J, Zhao Q, Wang G, Yang C, Xu Y, Li Y, et al. Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis. Cytokine. 2016;81:10–4.

    Article  CAS  PubMed  Google Scholar 

  19. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74:1–13.

    Article  CAS  PubMed  Google Scholar 

  20. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017;2017:3908061.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jethwa H, Bowness P. The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. Clin Exp Immunol. 2016;183:30–6.

    Article  CAS  PubMed  Google Scholar 

  22. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10:864–71.

    Article  CAS  PubMed  Google Scholar 

  23. Azizi G, Simhag A, El Rouby NM, Mirshafiey A. Th22 cells contribution in immunopathogenesis of rheumatic diseases. Iran J Allergy Asthma Immunol. 2015;14:246–54.

    PubMed  Google Scholar 

  24. Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012;7:e31000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Campbell DJ. Control of regulatory T cell migration, function, and homeostasis. J Immunol. 2015;195:2507–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ciccia F, Accardo-Palumbo A, Giardina A, Di Maggio P, Principato A, Bombardieri M, et al. Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum. 2010;62:3625–34.

    Article  CAS  PubMed  Google Scholar 

  27. Maksymowych WP. Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag. 2007;3:1125–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Wanders A, Heijde Dv, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756–65.

    Article  CAS  PubMed  Google Scholar 

  29. Elyan M, Khan MA. The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis. Curr Rheumatol Rep. 2006;8:255–9.

    Article  CAS  PubMed  Google Scholar 

  30. Nazeri S, Khadem Azarian S, Fattahi MJ, Sedaghat R, Tofighi Zavareh F, Aghazadeh Z, et al. Preclinical and pharmacotoxicology evaluation of α-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property. Immunopharmacol Immunotoxicol. 2017;39:59–65.

    Article  CAS  PubMed  Google Scholar 

  31. Mirshafiey A, Mortazavi-Jahromi SS, Taeb M, Cuzzocrea S, Esposito E. Evaluation of the effect of α-L-guluronic acid (G2013) on COX-1, COX-2 activity and gene expression for introducing this drug as a novel NSAID with immunomodulatory property. Recent Pat Inflamm Allergy Drug Discov. 2018;12:162–168.

    Article  CAS  PubMed  Google Scholar 

  32. Afraei S, Azizi G, Zargar SJ, Sedaghat R, Mirshafiey A. New therapeutic approach by G2013 in experimental model of multiple sclerosis. Acta Neurol Belg. 2015;115:259–66.

    Article  PubMed  Google Scholar 

  33. Mirshafiey A, Hosseini S, Afraei S, Rastkari N, Zavareh FT, Azizi G. Anti-aging property of G2013 molecule as a novel immunosuppressive agent on enzymatic and non-enzymatic oxidative stress determinants in rat model. Curr Drug Discov Technol. 2016;13:25–33.

    Article  CAS  PubMed  Google Scholar 

  34. Taeb M, Mortazavi-Jahromi SS, Jafarzadeh A, Mirzaei MR, Mirshafiey A. An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs. Biomed Pharmacother. 2017;90:262–67.

    Article  CAS  PubMed  Google Scholar 

  35. Arjomand Fard N, Tabrizian N, Mirzaei R, Hadjati J, Tofighi Zavareh F, Salehi Nodeh AR, et al. Efficacy and safety of G2013 as a novel immunosuppressive agent on differentiation, maturation and function of human dendritic cells. Iran J Public Health. 2017;46:216–21.

    PubMed  PubMed Central  Google Scholar 

  36. Hajivalili M, Pourgholi F, Majidi J, Aghebati-Maleki L, Movassaghpour AA, Samadi Kafil H, et al. G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner. Cell Mol Biol (Noisy-le-grand). 2016;62:1–5.

    CAS  Google Scholar 

  37. Mortazavi Jahromi SS, Jamshidi MM, Yousefi M, Navabi SS, Motamed N, Zavareh FT, et al. Inhibitory effect of G2013 molecule as a novel immunomodulatory agent, on miR-155 gene expression in HEK-Blue hTLR4 cell line. Eur J Inflamm. 2016;14:86–92.

    Article  Google Scholar 

  38. Mortazavi-Jahromi SS, Farazmand A, Motamed N, Navabi SS, Mirshafiey A. Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway. Int Immunopharmacol. 2018;55:323–29.

    Article  CAS  PubMed  Google Scholar 

  39. Sharifi L, Mohsenzadegan M, Aghamohammadi A, Rezaei N, Zavareh FT, Bokaie S, et al. Immunomodulatory effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in human mononuclear cells. Curr Drug Discov Technol. 2018;15:123–131.

    Article  CAS  PubMed  Google Scholar 

  40. Rezaiemanesh A, Abdolmaleki M, Abdolmohammadi K, Aghaei H, Pakdel FD, Fatahi Y, et al. Immune cells involved in the pathogenesis of ankylosing spondylitis. Biomed Pharmacother. 2018;100:198–204.

    Article  CAS  PubMed  Google Scholar 

  41. Guo Y, Xing E, Song H, Feng G, Liang X, An G, et al. Therapeutic effect of dioscin on collagen-induced arthritis through reduction of Th1/Th2. Int Immunopharmacol. 2016;39:79–83.

    Article  CAS  PubMed  Google Scholar 

  42. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2015;63:435–49.

    Article  CAS  Google Scholar 

  43. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58:2307–17.

    Article  PubMed  Google Scholar 

  44. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60:1647–56.

    Article  CAS  PubMed  Google Scholar 

  45. Xueyi L, Lina C, Zhenbiao W, Qing H, Qiang L, Zhu P. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol. 2013;33:151–61. 

    Article  CAS  PubMed  Google Scholar 

  46. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, et al. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006;290:G827–38.

    Article  CAS  PubMed  Google Scholar 

  47. Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci. 2010;58:225–7.

    Article  CAS  PubMed  Google Scholar 

  48. El-Zayadi AA, Jones EA, Churchman SM, Baboolal TG, Cuthbert RJ, El-Jawhari JJ, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology (Oxford). 2017;56:488–93.

    CAS  Google Scholar 

  49. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.

    Article  CAS  PubMed  Google Scholar 

  50. Wu Y, Ren M, Yang R, Liang X, Ma Y, Tang Y, et al. Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Res Ther. 2011;13:R29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wen JT, Zhang DH, Fang PF, Li MH, Wang RJ, Li SH. Role of Th1/Th2 cytokines in the diagnosis and prognostic evaluation of ankylosing spondylitis. Genet Mol Res. 2017;16. https://doi.org/10.4238/gmr16019322.  

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box 14155-6446, Tehran, Iran

    Seyed Shahabeddin Mortazavi-Jahromi, Sepideh Nazeri, Mona Oraei & Abbas Mirshafiey

  2. Department of Immunology, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

    Fahimeh Jafarnezhad-Ansariha

Authors
  1. Seyed Shahabeddin Mortazavi-Jahromi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sepideh Nazeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fahimeh Jafarnezhad-Ansariha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mona Oraei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abbas Mirshafiey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abbas Mirshafiey.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and consent to participate

The study was approved by the ethics committee of Tehran University of Medical Sciences (TUMS) and followed by an issued approval (clinical trial identifier: IRCT2016091813739N4). Written informed consent was obtained from all patients.

Consent for publication

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mortazavi-Jahromi, S., Nazeri, S., Jafarnezhad-Ansariha, F. et al. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties. Immunol Res 67, 108–115 (2019). https://doi.org/10.1007/s12026-018-9042-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-018-9042-3

Keywords

Search

Navigation